GT Biopharma is trading at $7.11 (-5.07%) after continued selling followed its September 15, 2026 announcement of a $7.45 million private placement involving convertible preferred stock and warrants.

  • The decline extends losses from September 17 and September 16, despite biotechnology stocks gaining 2.55%, indicating company-specific financing pressure rather than sector weakness.
  • GTB-5550’s FDA-cleared multiple-myeloma indication is positive, but trial initiation depends on grant funding.